OpenLobby.EU
Explore

Hologic BV

Hologic is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment.

Lobbying Activity

Response to Gender Equality Strategy 2026-2030

23 Jul 2025

Hologic welcomes the opportunity to contribute to this public consultation organized by DG JUST on the European Commissions work on Gender Equality, as well as the Commissions Communication on a Roadmap for Womens Rights and its Annex. Each of these important initiatives will advance the discussion on addressing gender disparities, especially in health and move towards actionable goals and initiatives. We particularly welcome the Roadmap defining the highest standards of health (physical and mental health) for women as a key principle. Addressing womens health appropriately translates to offering a lifelong roadmap for generational health and wellness for women. There are over 230 million women in the EU (approx 50% of the population), with a similar number projected for 2040, the health of whom contributes to the health of their families, communities, societies and countries. As an advocate for womens health, Hologic is committed to improving and saving womens lives through early detection and effective treatment. We invest heavily to elevate awareness and inspire action, to break down structural barriers that have historically and disproportionately affected women and currently prevent them from receiving the care they need. The evidence we present comes from the Hologic Global Womens Health Index (HGWHI) and supports this statement - Within the EU, the state of womens health is not improving. The HGWHI, now in its fourth year, measures womens perceptions of five dimensions of their health preventive care, individual health, emotional health, opinions on health and safety, and meeting their basic needs. Together, these five dimensions have been found to account for more than 70% of variances in a womans average life expectancy. The HGWHI data shows that women's health is stagnating around the world, even as the COVID-19 pandemic wanes. Within the EU, the HGWHI clearly spotlights key underlying health factors which prevent the full inclusion of women in society and their participation in economic activities and growth. Key data includes: 11% of EU women couldnt afford shelter and 14% couldnt afford food; The individual health of women in the EU has deteriorated: 33% of EU women say they spent a lot of the previous day in physical pain and 27% have health problems that keep them from doing normal activities; More than 3 in 10 women dont feel safe walking alone at night in their own community; Nearly 4 in 10 EU women are dissatisfied with the availability of quality healthcare where they live; More women across all age groups in the EU (73%) believe that gender based (domestic) violence is widespread than in Year 3; Testing rates are low for many key diseases and conditions, also for EU women: 45% for high blood pressure, 20% for any type of cancer, 25% for diabetes and 8% for STIs. The EU testing for STIs is even lower than the global 10%. Hologic calls on the European Commission to appropriately address health inequalities including access to care in the Gender Equality Strategy, along with the wider impact of womens unequal participation in society. Specifically, we call on the Commission to develop an Action Plan on Womens Health, driven by evidence and data, as a key component to drive change, and in support of existing national womens health strategies. A European Action Plan on Women's Health, including safety, basic needs, and key health dimensions, would improve awareness, access and affordability of healthcare for women across the region. To conclude, we welcome the opportunity to present this evidence as part of this public consultation on the Gender Equality Strategy. Gender Equality in all its forms, will enable healthy women to participate, engage and contributemore fully tofamily life, society and the economy, and finally, enable themto seize opportunities to shape their own future.
Read full response

Meeting with Marina Kaljurand (Member of the European Parliament, Rapporteur)

13 May 2025 · LIBE Opinion on Gender Equality Strategy

Meeting with Heléne Fritzon (Member of the European Parliament)

30 Apr 2025 · Strategi för kvinnors hälsa

Meeting with András Tivadar Kulja (Member of the European Parliament)

24 Apr 2025 · Women's health

Meeting with Tilly Metz (Member of the European Parliament) and Kreab Worldwide

11 Dec 2024 · Women's health

Meeting with András Tivadar Kulja (Member of the European Parliament)

11 Dec 2024 · Women’s health,

Meeting with Elena Nevado Del Campo (Member of the European Parliament)

11 Dec 2024 · EU's women health

Meeting with Billy Kelleher (Member of the European Parliament)

12 Sept 2024 · Womens' Health

Meeting with Barry Andrews (Member of the European Parliament)

12 Apr 2024 · Women's Health

Meeting with Lesia Radelicki (Cabinet of Commissioner Helena Dalli)

10 Apr 2024 · EU Women’s Health Strategy

Meeting with Evelyn Regner (Member of the European Parliament)

10 Jan 2024 · Women's Health

Meeting with Carina Ohlsson (Member of the European Parliament)

14 Dec 2023 · Digital dialog om Women's Health Strategy

Meeting with Laura Ballarín Cereza (Member of the European Parliament)

6 Nov 2023 · Women´s Health

Meeting with Sirpa Pietikäinen (Member of the European Parliament)

6 Sept 2023 · EU Women's Health Strategy

Meeting with Frances Fitzgerald (Member of the European Parliament)

19 Jul 2023 · Women's health

Meeting with Nicolás González Casares (Member of the European Parliament, Shadow rapporteur)

28 Jun 2023 · Medicines

Meeting with Michèle Rivasi (Member of the European Parliament)

28 Jun 2023 · santé

Meeting with Radka Maxová (Member of the European Parliament)

28 Jun 2023 · Gender disparities in health

Meeting with Irène Tolleret (Member of the European Parliament)

21 Mar 2023 · Santé des femmes

Meeting with Dolors Montserrat (Member of the European Parliament, Rapporteur)

14 Sept 2022 · Cancer early diagnosis

Response to Cancer Screening Recommendation

21 Feb 2022

HOLOGIC is pleased about the opportunity to respond to the European Commission’s Call for Evidence ahead of the adoption of its Proposal for an Updated Council Recommendation on Cancer Screening. In the document uploaded you will find a comprehensive update on most relevant evidence in the fields of breast cancer screening and cervical cancer screening. Based on this evidence we are giving concrete recommendations for enhancing both breast and cervical cancer screening programs. In the appendix of the document all latest publications on the topics are listed. Breast cancer: In a 2021 update to the breast cancer screening guidelines the ECIBC (European Initiative against Breast Cancer) has recommended to use Digital Breast Tomosynthesis (DBT) in screening in women with high mammographic breast density. Scientific evidence for the advantage of DBT in routine breast cancer screening for all women and especially for women with dense breast is increasing further. High mammographic breast density should be recognized as an easy identifiable risk factor for breast cancer also in national breast cancer screening programs across Europe. Initiatives are required to finally implement Digital Breast Tomosynthesis in national breast cancer screening programs. Cervical Cancer: Sufficient evidence is available for mRNA-based HPV tests for cervical cancer screening. mRNA-based HPV tests come with a higher specificity than DNA-based HPV tests (less positive HPV results without any pre-stages of cancer) and with the same sensitivity as DNA-based HPV tests. After positive evidence assessments of many countries like UK, France, or Germany, millions of women in Europe have already been tested with mRNA-based HPV tests in national screening programs. We therefore highly recommend to include mRNA-based HPV testing in the European Commission cervical cancer screening guidelines. The option of home-collection of HPV tests can compromise sample quality and participation rate of women, who have regularly attended professional sampling so far. We therefore highly recommend offering self-sampling to non-responders only. Liquid-based cytology has proven to provide a better sensitivity to detect pre-stages of cervical cancer than conventional cytology. The automation and standardization of LBC further avoids cervical samples that finally cannot be rated. Cytology triage after a positive HPV test should be performed with LBC or Digital Cytology using AI as a quality assurance.
Read full response

Meeting with Irena Joveva (Member of the European Parliament)

23 Sept 2020 · Women's health and beating cancer